New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
van den Boogaard
Jossy
J
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. jossyvandenboogaard@gmail.com
Kibiki
Gibson S
GS
Kisanga
Elton R
ER
Boeree
Martin J
MJ
Aarnoutse
Rob E
RE
D000818:Animals; D000995:Antitubercular Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000009:adverse effects; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000235:genetics; D012294:Rifamycins / Q000493:pharmacokinetics / Q000494:pharmacology; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology / Q000628:therapy*
D000995:Antitubercular Agents; D024841:Fluoroquinolones; D012294:Rifamycins